PrimaVu

PrimaVu was a clinical-stage biotechnology company focused on the development of innovative sustained-release therapies for ophthalmic diseases, particularly dry eye disease. The company's lead asset, PV-101, was a sustained-release cyclosporine insert designed to provide continuous therapeutic levels of medication to the ocular surface, potentially improving efficacy and patient adherence compared to standard eye drops. PrimaVu's technology utilized a proprietary delivery system to address the unmet needs of patients with chronic ocular surface conditions. In December 2020, the company was acquired by Ocular Therapeutix, a leader in ophthalmic drug delivery, to bolster its pipeline of ocular surface treatments. The acquisition integrated PrimaVu's cyclosporine program into Ocular Therapeutix's portfolio of hydrogel-based therapies.